Wedbush Starts Audentes Therapeutics (BOLD) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/31/2026
- Take-Two stock drops as GTA 6 leaks continue
- GameStop posts higher income despite revenue drop in Q2 2026
- At least eight die, 18 missing after ferry capsizes off North Cyprus
- Manhunt underway after woman killed, several injured at Swiss rave shooting
- Goldman Sachs raises humanoid robot forecast, sees auto role
Cowen Starts Audentes Therapeutics (BOLD) at Outperform
August 15, 2016 6:56 AM EDTCowen initiated coverage on Audentes Therapeutics (NASDAQ: BOLD) with an Outperform rating.
For an analyst ratings summary and ratings history on Audentes Therapeutics click here. For more ratings news on Audentes Therapeutics click here.
Shares of Audentes Therapeutics closed at $14.70 yesterday.
... More